(BELG J MED ONCOL 2013;7:15–19)
By: A. Awada MD, PhD, L. Annemans , D. Broeckx PharmD, P. Pauwels MD, PhD, S. Simoens , S. Van Belle MD, PhD, E. van Cutsem MD, PhD, E. Van Hoof PhD, MSc, J. De Grève MD, PhD
(BELG J MED ONCOL 2013;7:15–19)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
